Current Challenges and Unresolved Problems in Hypertensive Disease

Medical Clinics of North America

Volumn 93, Issue 3, 2009, Pages 527-540

  Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Heart; Hypertension; Kidney; Management; Pathophysiology; Salt; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; SODIUM CHLORIDE;

ANTIHYPERTENSIVE THERAPY; APOPTOSIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE ACTIVITY; DRUG MEGADOSE; ECG ABNORMALITY; EPICARDIUM; ESSENTIAL HYPERTENSION; FIBROSIS; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS FILTRATION RATE; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; METABOLIC DISORDER; MICROALBUMINURIA; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PASSIVE SMOKING; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SMOKING; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTOLIC HYPERTENSION; TARGET ORGAN; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; RISK FACTORS; SMOKING; SODIUM, DIETARY;

EID: 65449131957     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.02.004     Document Type: Review

References (58)

1. Frohlich E.D., Tarazi R.C., and Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 44 (1971) 446-455
2. Tarazi R.C., Miller A., Frohlich E.D., et al. Electrocardiographic changes reflecting left atrial abnormality in hypertension. Circulation 34 (1966) 818-822
3. Dunn F.G., Chandraratna P., de Carvalho J.G.R., et al. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 39 (1977) 789-795
4. Kannel W.B., Dawber T.R., Kagen A., et al. Factors of risk in the development of coronary heart disease: six year follow-up experience. The Framingham Study. Ann Intern Med 55 (1961) 33-56
5. Frohlich E.D., Apstein C., Chobanaian A.V., et al. The heart in hypertension. N Engl J Med 327 (1992) 998-1008
6. Frohlich E.D., and Tarazi R.C. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?. Am J Cardiol 44 (1979) 959-963
7. Frohlich E.D. Hemodynamics and other determinants in development of left ventricular hypertrophy: conflicting factors in its regression. Fed Proc 42 (1983) 2709-2715
8. Frohlich E.D. Clinical conference: hypertensive cardiovascular disease: a pathophysiological assessment. Hypertension 6 (1984) 934-939
9. Frohlich E.D. State of the art. The heart in hypertension: unresolved conceptual challenges. Hypertension 11 (1988) 19-24
10. Frohlich E.D. (State of the Art): the first Irvine H. Page lecture: the mosaic of hypertension: Past, present, and future. J Hypertens 6 (1988) S2-S11
11. Sasaki O., Kardon M.B., Pegram B.L., et al. Aortic distensibility and left ventricular pumping ability after methyldopa in Wistar-Kyoto and spontaneously hypertensive rats. J Vascular Med Biol 1 (1989) 59-66
12. Natsume T., Kardon M.B., Pegram B.L., et al. Ventricular performance in spontaneously hypertensive rats with reduced cardiac mass. Cardiovasc Drugs Ther 3 (1989) 433-439
13. Frohlich E.D. Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol 21 Suppl V (1989) 3-10
14. Frohlich E.D., and Sasaki O. Dissociation of changes in cardiovascular mass and performance with angiotensin converting enzyme inhibitors in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol 16 (1990) 1492-1499
15. Frohlich E.D. Regression of cardiac hypertrophy and left ventricular pumping ability post-regression. J Cardiovasc Pharmacol 17 (1991) 81-86
16. Frohlich E.D., and Horinaka S. Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension 18 (1991) 2-7
17. Frohlich E.D., Sasaki O., Chien Y., et al. Changes in cardiovascular mass, left ventricular pumping ability, and aortic distensibility after calcium antagonist in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens 10 (1992) 1369-1378
18. Frohlich E.D. Risk mechanisms in hypertensive heart disease. Hypertension 34 (1999) 782-789
19. In: Safar M.E., and O'Roarke M.F. (Eds). Arterial stiffness in hypertension, Volume 23 of Handbook of Hypertensioin (Series Editors: Birkenhäger WH and Ried JL) (2006), Elsevier BV, Amsterdam
20. Gomez D.M. Evaluation of renal resistances with special reference to changes in essential hypertension. J Clin Invest 30 (1951) 1143-1155
21. Ono H., Ono Y., and Frohlich E.D. Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics. Hypertension 26 (1995) 249-255
22. Ono H., Ono Y., and Frohlich E.D. ACE inhibition prevents and reverses L-NAME exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 27 (1996) 176-183
23. Frohlich E.D. Arthur C. Corcoran memorial lecture: influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 29 (1997) 519-524
24. Francischetti A., Ono H., and Frohlich E.D. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with or without L-NAME. Hypertension 31 (1998) 795-801
25. Susic D., and Frohlich E.D. Nephroprotective effects of antihypertensive drugs in essential hypertension. J Hypertens 16 (1998) 555-567
26. Ono H., Ono Y., and Frohlich E.D. L-Arginine reverses severer nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens 17 (1999) 121-128
27. Nakamura Y., Oho H., and Frohlich E.D. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 34 (1999) 273-278
28. Nakamura Y., Ono H., Zhou X., et al. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoptotection in L-NAME/SHR rats. Hypertension 37 (2001) 1262-1267
29. Zhou X., and Frohlich E.D. Functional and structural involvement of afferent and efferent glomerular arterioles in hypertension. Am J Kidney Dis 37 (2001) 1092-1097
30. Ono H., Ono Y., Takanohashi A., et al. Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in SHR. Hypertension 38 (2001) 1300-1306
31. Zhou X., Ono H., Ono Y., et al. N- and L-type calcium channel antagonistic improves glomerular dynamics, reverses severe nephrosclerosis and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 20 (2002) 993-1000
32. Frohlich E.D. Clinical management of the obese hypertensive patient. Cardiol Rev 10 (2002) 127-138
33. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee (2003). The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
34. International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 21 (2003) 651-663
35. Ono Y., Ono H., and Frohlich E.D. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 14 (1996) 823-828
36. 1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 289 (2005) F871-F879
37. Reisin E., Frohlich E.D., Messerli F.H., et al. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 98 (1983) 315-319
38. Frohlich E.D. The metabolic syndrome: there's little that's new under the sun. J Cardiometab Syndr 1 5 (2006) 293-294
39. Herrick W.W. Early reports on frequency of diabetes in patients with hypertension. In: Joslin E.P. (Ed). The treatment of diabetes mellitus: the experience of the Joslin clinic in patients under and over 50 years of age. 3rd edition (1923), Lea & Febiger, Philadelphia
40. Frohlich E.D. The salt conundrum: a hypothesis. Hypertension 50 (2007) 161-166
41. Kurlansky M. Salt: a World history (2003), Penguin Books, New York
42. Ambard L., and Beaujard E. Causes de l'hypertension arterialle. Arch Med Gen Trop 1 (1904) 520-533
43. Weinberger M.H., Miller J.Z., Luft F.C., et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 8 Suppl II (1986) 127-134
44. Chrysant S.G., Walsh G.M., Kem D.C., et al. Hemodynamic and metabolic evidence of salt sensitivity in spontaneously hypertensive rats. Kidney Int 15 (1979) 33-37
45. MacPhee A.A., Blakeslley H.L., Graci K.A., et al. Altered cardiac beta-adrenergic receptors in SHR rats receiving salt excess. Clin Sci 59 Suppl VI (1980) 169-170
46. Frohlich E.D., Chien Y., Sosoko S., et al. Relationships between dietary sodium intake, hemodynamic and cardiac mass in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Am J Physiol 264 (1993) R30-R34
47. Ahn J., Varagic J., Slama M., et al. Cardiac structural and functional responses to salt loading in SHR. Am J Physiol Heart Circ Physiol 287 (2004) H767-H772
48. Varagic J., Frohlich E.D., Diez J., et al. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol 290 (2006) H1503-H1509
49. Williams J.S., Solomon S.D., Crivaro M., et al. Dietary sodium intake modulates myocardium relaxation responsiveness to angiotensin II. Transgenic Res 48 (2006) 49-54
50. Varagic J., Frohlich E.D., Susic D., et al. AT-1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 294 (2008) H853-H868
51. Matavelli L.C., Zhou X., Varagic J., et al. Salt loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 292 (2007) H814-H819
52. Susic D., Zhou X., and Frohlich E.D. Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats. Am J Nephrol 29 (2009) 639-645
53. Cook N.R., Cutler J.A., Obazanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334 (2007) 885-894
54. Tunstall-Pedoe H., Woodward M., Tavendale R., et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study. BMJ 351 (1997) 722-729
55. Toumilehto J., Iousilahti P., Restenyte D., et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 357 (2001) 848-851
56. Frohlich E.D. The role of salt in hypertension: the complexity seems to become clearer. Nat Clin Pract Cardiovasc Med 5 (2008) 2-3
57. Partovian C., Benetos A., Pommies J.P., et al. Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin. Am J Physiol 274 (1998) H1423-H1428
58. Du Cailar G., Ribstein J., and Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 15 (2002) 222-229